Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Rating of "Buy" by Brokerages

Key Points

• Crescent Biopharma, Inc. (NASDAQ:CBIO) has received an average rating of "Buy" from five analysts, with a target price averaging $25.50.
• The company recently reported a quarterly loss of ($4.93) earnings per share, missing the consensus estimate by ($2.24).
• Despite a current trading price of $13.08, the stock has experienced significant volatility, showing a 12-month low of $10.83 and a high of $63.00.

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have received a consensus recommendation of "Buy" from the five analysts that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.50.

A number of analysts have recently issued reports on CBIO shares. Lifesci Capital upgraded Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price for the company in a report on Wednesday, June 18th. Wall Street Zen cut shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 2nd. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. HC Wainwright assumed coverage on shares of Crescent Biopharma in a research note on Monday. They issued a "buy" rating and a $25.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Crescent Biopharma in a research note on Wednesday, June 25th. They issued a "buy" rating and a $28.00 target price for the company.

Institutional Investors Weigh In On Crescent Biopharma

An institutional investor recently bought a new position in Crescent Biopharma stock. Jefferies Financial Group Inc. purchased a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 27,096 shares of the biopharmaceutical company's stock, valued at approximately $437,000. Jefferies Financial Group Inc. owned about 0.14% of Crescent Biopharma as of its most recent filing with the Securities and Exchange Commission. 75.19% of the stock is currently owned by institutional investors and hedge funds.

Crescent Biopharma Stock Performance

NASDAQ CBIO traded up $0.03 on Monday, hitting $13.93. The stock had a trading volume of 56,604 shares, compared to its average volume of 41,978. The firm's 50-day simple moving average is $13.88. The stock has a market cap of $272.33 million, a PE ratio of -0.40 and a beta of 1.51. Crescent Biopharma has a one year low of $10.83 and a one year high of $63.00.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($4.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.69) by ($2.24). On average, equities analysts predict that Crescent Biopharma will post -0.16 EPS for the current year.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.